Hemodynamic changes with liver fibrosis measured by dynamic contrast-enhanced MRI in the rat

Magnetic Resonance in Medical Sciences

Volumn 5, Issue 2, 2006, Pages 65-71

  Kubo, Hitoshi ^a   Harada, Masafumi ^a   Ishikawa, Makoto ^b   Nishitani, Hiromu ^c  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Dynamic MRI; Fibrosis; Hemodynamics; Liver; Pharmacokinetics

Indexed keywords

CARBON TETRACHLORIDE; CONTRAST MEDIUM; GADOLINIUM PENTETATE; THIOACETAMIDE;

ABDOMINAL AORTA; ANIMAL; AREA UNDER THE CURVE; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EXPERIMENTAL LIVER CIRRHOSIS; HALF LIFE TIME; IMAGE ENHANCEMENT; LIVER CIRCULATION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; RAT; SIGNAL PROCESSING; WISTAR RAT;

ANIMALS; AORTA, ABDOMINAL; AREA UNDER CURVE; CARBON TETRACHLORIDE; CONTRAST MEDIA; GADOLINIUM DTPA; HALF-LIFE; IMAGE ENHANCEMENT; LIVER CIRCULATION; LIVER CIRRHOSIS, EXPERIMENTAL; MAGNETIC RESONANCE IMAGING; MALE; RATS; RATS, WISTAR; SIGNAL PROCESSING, COMPUTER-ASSISTED; THIOACETAMIDE;

EID: 39049175151     PISSN: 13473182     EISSN: 18802206     Source Type: Journal    
DOI: 10.2463/mrms.5.65     Document Type: Article

References (14)

1. Ritschel WA. Handbook of basic pharmacokinetics. Hamilton, IL: Drug Intelligence Publications, 1976; 173-179.
2. Bourne DWA. Mathematical modeling of pharmacokinetic data. Lancaster, Pa.: Technomic Publishing, 1995; 19-33.
3. Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 1978; 6:547-558.
4. Schuhmann-Giampieri G, Frenzel T, Schmitt-Willich H. Pharmacokinetis in rats, dogs and monkeys of a gadolinium chelate used as a liverspeci fic contrast agent for magnetic resonance imaging. Arzneimitteforschung 1993; 43:927-931.
5. Iimuro Y, Nishio T, Morimoto T, et al. Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. Gastroenterology 2003; 124:445-458.
6. Bhimani EK, Serracino-Inglott F, Sarela AI, Batten JJ, Mathie RT. Hepatic and mesenteric nitric oxide synthase expression in a rat model of CCl(4)-induced cirrhosis. J Surg Res 2003; 113: 172-178.
7. Kanno K, Tazuma S, Chayama K. AT1A-deficient mice show less severe progression of liver fibrosis induced by CCl(4). Biochem Biophys Res Commun 2003; 308:177-183.
8. Onishi Y. Calculation of compartment model analysis using a spreadsheet program. Jpn J Radiol Technol 1998; 54:1336-1341.
9. Van Beers BE, Leconte I, Materne R, Smith AM, Jamart J, Horsmans Y. Hepatic perfusion parameters in chronic liver disease: dynamic CT measurements correlated with disease severity. AJR Am J Roentgenol 2001; 176:667-673.
10. Materne R, Van Beers BE, Smith AM, et al. Noninvasive quantification of liver perfusion with dynamic computed tomography and a dual-input one-compartment model. Clin Sci 2000; 99:517-525.
11. Funabasama S, Tsushima Y, Sanada S, Inoue K. [Hepatic perfusion CT imaging analyzed by the dual-input one-compartment model]. Nippon Hoshasen Gijutsu Gakkai Zasshi [Jpn J Radiol Technol] 2003; 59:1548-1554. (in Japanese)
12. Suzuki K, Hayashi N, Miyamoto Y, et al. Expression of vascular permeability factorWvascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res 1996; 56:3004-3009.
13. Ishikawa K, Mochida S, Mashiba S, et al. Expressions of vascular endothelial growth factor in nonparenchymal as well as parenchymal cells in rat liver after necrosis. Biochem Biophys Res Commun 1999; 254:587-593.
14. Rosmorduc O, Wendum D, Corpechot C, et al. Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis. Am J Pathol 1999; 155:1065-1073.